Patient-derived xenografts and organoids model therapy response in prostate cancer

Abstract

Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe an androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1 -like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.

References 70

1. 1.

   Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356-387.

   Not in our library10.1016/j.ejca.2018.07.005

2. 2.

   Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014;371:424-433.

   Not in our library10.1056/nejmoa1405095

3. 3.

   de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011;364:1995-2005.

   Not in our library10.1056/nejmoa1014618

4. 4.

   Byrne AT, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer. 2017;17:254-268.

   Not in our library10.1038/nrc.2016.140

5. 5.

   Wang Y, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005;64:149-159.

   Not in our library10.1002/pros.20225

6. 6.

   Wetterauer C, et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice. Prostate. 2015;75:585-592.

   Not in our library10.1002/pros.22939

7. 7.

   Navone NM, et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018;78:1262-1282.

   Not in our library10.1002/pros.23701

8. 8.

   Lin D, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014;74:1272-1283.

   Not in our library10.1158/0008-5472.can-13-2921-t

9. 9.

   Pauli C, et al. Personalized In vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462-477.

   Not in our library10.1158/2159-8290.cd-16-1154

10. 10.

    Raheem O, et al. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J. Transl. Med. 2011;9:185.

    Not in our library10.1186/1479-5876-9-185

11. 11.

    Williams ES, et al. Generation of prostate cancer patient derived xenograft models from circulating tumor cells. J. Vis. Exp. 2015;105:53182.

    Not in our library10.3791/53182

12. 12.
    Patient derived organoids to model rare prostate cancer phenotypes · 2018

    No notice
13. 13.

    Nguyen HM, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an­­d serve as models for evaluating cancer therapeutics. Prostate. 2017;77:654-671.

    Not in our library10.1002/pros.23313

14. 14.

    Navone NM, et al. Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018;78:1262-1282.

    Not in our library10.1002/pros.23701

15. 15.

    Palanisamy N, et al. The MD Anderson Prostate Cancer Patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin. Cancer Res. 2020;26:4933-4946.

    Not in our library10.1158/1078-0432.ccr-20-0479

16. 16.

    Priolo C, et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 2010;176:1901-1913.

    Not in our library10.2353/ajpath.2010.090873

17. 17.

    Klein KA, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 1997;3:402-408.

    Not in our library10.1038/nm0497-402

18. 18.
    Application of Cancer Organoid Model for Drug Screening and Personalized Therapy · 2019

    No notice
19. 19.
    Xenograft and organoid model systems in cancer research · 2019

    No notice
20. 20.

    Granat LM, et al. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology. Anim. Models Exp. Med. 2019;2:150-161.

    Not in our library10.1002/ame2.12077

21. 21.

    Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920-926.

    Not in our library10.1126/science.aao2774

22. 22.

    McCulloch DR, et al. BM18: a novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis. Prostate. 2005;65:35-43.

    Not in our library10.1002/pros.20255

23. 23.

    Craft N, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030-5036.

    Not in our library

24. 24.

    Chakraborty G. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. 2020;26:2047.

    Not in our library10.1158/1078-0432.ccr-19-1570

25. 25.
    Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer · 2014

    No notice
26. 26.
    The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact · 2019

    No notice
27. 27.

    Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.

    Not in our library10.1038/nature12477

28. 28.

    Popova T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72:5454-5462.

    Not in our library10.1158/0008-5472.can-12-1470

29. 29.

    Niu B, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015-1016.

    Not in our library10.1093/bioinformatics/btt755

30. 30.

    Abida, W., et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. 2018.

    Not in our library10.1001/jamaoncol.2018.5801

31. 31.

    Barata P, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J. Immunother. Cancer. 2020;8:e001065.

    Not in our library10.1136/jitc-2020-001065

32. 32.
    Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer · 2018

    No notice
33. 33.

    Rabinovich GA, Conejo-García JR. Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J. Mol. Biol. 2016;428:3266-3281.

    Not in our library10.1016/j.jmb.2016.03.021

34. 34.

    O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019;16:151-167.

    Not in our library10.1038/s41571-018-0142-8

35. 35.

    Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215-1228.

    Not in our library10.1016/j.cell.2015.05.001

36. 36.

    Grasso CS, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239.

    Not in our library10.1038/nature11125

37. 37.
    SPOP mutation leads to genomic instability in prostate cancer · 2015

    No notice
38. 38.

    Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011-1025.

    Not in our library10.1016/j.cell.2015.10.025

39. 39.

    Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012;44:685-689.

    Not in our library10.1038/ng.2279

40. 40.

    Rescigno P, et al. Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer. J. Clin. Oncol. 2018;36:5064-5064.

    Not in our library10.1200/jco.2018.36.15_suppl.5064

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.